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ABSTRACT
We previously reported that miR-1 is among the
most consistently down-regulated miRs in primary
human prostate tumors. In this follow-up study, we
further corroborated this finding in an independent
data set and made the novel observation that miR-1
expression is further reduced in distant metastasis
and is a candidate predictor of disease recurrence.
Moreover, we performed in vitro experiments to
explore the tumor suppressor function of miR-1.
Cell-based assays showed that miR-1 is epi-
genetically silenced in human prostate cancer.
Overexpression of miR-1 in these cells led to
growth inhibition and down-regulation of genes in
pathways regulating cell cycle progression, mitosis,
DNA replication/repair and actin dynamics. This ob-
servation was further corroborated with protein ex-
pression analysis and 30-UTR-based reporter assays,
indicating that genes in these pathways are either
direct or indirect targets of miR-1. A gene set enrich-
ment analysis revealed that the miR-1-mediated
tumor suppressor effects are globally similar to
those of histone deacetylase inhibitors. Lastly, we
obtained preliminary evidence that miR-1 alters the
cellular organization of F-actin and inhibits tumor cell
invasion and filipodia formation. In conclusion, our
findings indicate that miR-1 acts as a tumor suppres-
sor in prostate cancer by influencing multiple
cancer-related processes and by inhibiting cell pro-
liferation and motility.
INTRODUCTION
MicroRNAs (miRs) are small non-coding RNAs that
control mRNA stability and the translation of target
mRNAs by binding to regulatory sites which are mostly
located in the 30-untranslated region (UTR) of the tran-
script (1). Expression of these non-coding RNAs is altered
in human tumors, resulting in distinct miR networks for
the various tumor types (2–4). Numerous miRs have been
shown to display tumor suppressor activity while others
act like oncogenes (5–11). Alterations in the expression of
these miRs have been linked to cancer development and
metastasis and may predict disease outcome and response
to therapy (6,8,12–17). Known mechanisms that cause
dysregulated miR expression in tumors include genomic
alterations and epigenetic promoter silencing (18–20). In
addition, feedback loops between miRs and their targets
are sometimes modiﬁed in cancer cells because these cells
commonly express transcripts encoding growth-regulatory
genes with shortened 30-UTRs (21,22).
We and others have shown that miRs and components
of the intracellular miR machinery show widespread
dysregulation in prostate cancer biology (3,10,11,23–30).
However, we have still an incomplete understanding of
how prostate cancer-associated miRs affect disease pro-
gression because few studies have characterized miRs
that are functionally linked to disease recurrence and
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that miR-1 is a tumor suppressor gene in prostate cancer
that can serve as a prognostic marker based on our prior
observation that miR-1 was commonly under-expressed in
primary human prostate tumors when compared with the
surrounding non-cancerous tissue (26).
miR-1 is encoded by the miR-1-133 cluster which has
two copies (at 18q11 and 20q13) in the human genome
producing identical mature miR sequences for miR-1
and miR-133. miR-1 is abundantly expressed in heart
and skeletal muscle tissue (33–35). It was recently
reported that miR-1 and miR-133, and also miR-206,
which is a functional homolog of miR-1, are among the
most frequently down-regulated miRs in solid human
cancers (4,36). Other studies showed that miR-1 is ex-
pressed in normal human epithelial cells, albeit at low
levels when compared to the heart, but silenced in
cancer cells (37,38). To further deﬁne the role of miR-1
in prostate cancer progression, we analyzed a large data
set consisting of primary tumors, disease metastases and
patients’ recurrence status (39). We also re-expressed
miR-1 in human prostate cancer cell lines. These studies
revealed that miR-1 is a novel candidate marker for
disease recurrence in prostate cancer and exhibits a
tumor suppressor activity that affects multiple pathways,
leading to higher order chromosomal and epigenetic alter-
ations globally similar to those of histone deacetylase
inhibitors.
MATERIALS AND METHODS
Cell culture and human prostate tissue samples
The human prostate cell lines, LNCaP, 22Rv1, PC-3 and
RWPE-1, were obtained from the American Type Culture
Collection (Manassas, VA, USA) and maintained as
indicated by the supplier. Fresh frozen human prostate
tissues were collected from prostate cancer patients after
prostatectomy under the IRB approved protocol ‘A case–
control study of prostate cancer in the greater Baltimore
area’, NCI IRB #05-C-N021. We prepared frozen serial
sections from tumor tissue and adjacent non-cancerous
tissue and conﬁrmed presence/absence of tumor in these
sections after review of a hematoxylin/eosin-stained
section by a pathologist. Genomic DNA was extracted
from these sections.
RNA isolation and expression analysis of mRNAs and
miRs in cell lines
Total RNA was isolated with TRIZOL reagent
(Invitrogen, Carlsbad, CA, USA). Expression proﬁles of
protein coding genes were analyzed on the GeneChip
Human Genome U133A 2.0 array following standard
protocols from Affymetrix (Santa Clara, CA, USA).
Three independent experiments were performed to
proﬁle cell lines. To determine large-scale miR expression
proﬁles, Ohio State University Comprehensive Cancer
Center (OSU) arrays were used following previously es-
tablished methods (40). A description of these arrays can
be found at ArrayExpress under the accession numbers
MEXP-258 and MEXP-1838. Normalized and raw
expression data from this study for both mRNAs and
miRs were deposited in GEO (http://www.ncbi.nlm.nih
.gov/geo) under the accession number GSE31620. GEO
also describes the V.4 microRNA platform under the
accession number GPL14184.
qRT-PCR analysis of miR expression
For quantiﬁcation of mature miRs, Human TaqMan
MicroRNA Assays (Applied Biosystems, Carlsbad, CA,
USA) and reagents from the TaqMan MicroRNA
Reverse Transcription Kit were used, as previously
reported (27). Expression levels of miRs were normalized
to U6 RNA levels and presented as 2
 Ct.
Analysis of epigenetic silenced miRs
LNCaP and 22Rv1 cells were treated with 5-Azacytidine
(5-AzaC) and/or trichostatin A (TSA) (Sigma, Saint
Louis, MO, USA) following similar schemes reported by
others (37). Brieﬂy, cells were plated at 1 10
6 cells per
10cm
2 for 48h and then treated with dimethylsulfoxide
(DMSO) as a control and 5-AzaC (5mM), and/or TSA
(0.3mM). For combined treatments, TSA was added
after 12h of pre-treatment with 5-AzaC or control. After
36h, cells were harvested for RNA extraction (n=4–5 per
treatment). OSU miRNA Version 4.0 arrays were used for
proﬁling miR expression levels. Raw GPR data ﬁles from
these experiments were imported into BRB array tools
using the MAS.5 median-based normalization. Probes
with low intensities (<10), minimum fold-change (i.e.
<20% of expression data values with at least a 1.5-fold
change in either direction from the gene’s median value)
and >50% missing data were excluded. Class comparisons
between treatments were carried out using randomized
block univariate t-tests across independent experiments.
Cloning of the miR-1-133 cluster into a lentiviral vector
Detailed information describing cloning of the miR-1-133
cluster into a lentiviral expression vector is provided in
Supplementary Data.
miR oligonucleotides and transient transfections
Pre-miR mimic (Ambion, TX, USA) or lock nucleic acid
(LNA) (Exiqon Inc.,Vedbaek, Denmark) oligonucleotides
were used at a 30-nM ﬁnal concentration in the experi-
ments. Cells were plated in 6-well plates at 2.5 10
5 cells
per well, allowed to grow for 48–72h and then switched to
antibiotic free media before being transfected with
lipofectamine 2000 (Invitrogen), as directed by the
manufacturer.
30-UTR reporter construct cloning and luciferase assays
Detailed information about the cloning of the 30-UTR
reporter constructs can be found in Supplementary
Data. For the luciferase assays, reporter plasmids and
miR oligos were co-reverse transfected using lipofectamine
2000 as suggested by the manufacturer (Invitrogen).
Brieﬂy, 200ng of plasmid DNA, 60pmol of pre-miR
oligos and 0.25ml lipofectamine were complexed individu-
ally (25ml total each) and added in various combinations
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4 cells in 96-well plates. Samples were
measured after 48h using Dual-Luciferase Reporter
Assay System (Promega, Madison, WI, USA) and read
on a Fluroskan Ascent FL Microplate Fluorometer
(Thermo Electron, Milford, MA, USA) following the
manufacturers’ procedures. Values are presented as the
ratio of renilla to ﬁreﬂy luciferase activity (n=6 per
treatment).
Cell cycle analysis with propidium iodide
Cells were transfected as described above with miR oligos
mimics and then harvested by trypsinization, washed three
times with PBS, ﬁxed with 70% cold ethanol before
being stained with a 5-mg/ml propidium iodide (Sigma,
MO, USA)/20ng/ml RNase A (Roche)/PBS solution
for 30min. At least 10000 events were analyzed for each
sample using a FACSCalibur cytometer (BD Biosciences,
Chicago, IL, USA), cell phase percentages were
determined using the FlowJo software (Ashland, OR,
USA).
Western blot analysis and antibodies
Cells were lysed in radioimmunoprecipitation assay buffer
(RIPA; Sigma) and 25–50mg protein per lane were
separated on SDS–polyacrylamide gels and transferred
to nitrocellulose membranes using an iBlot Dry
Blotting System (Invitrogen). Immunoblotting was per-
formed using the following primary antibodies using the
dilutions recommended by the supplier: Phospho-histone
H2AX (Ser139) (Cell Signaling Technology, Danvers,
MA, USA; #2577), H2A.X (#2595), histone H2A
(#2578), 53BP1 (#4937), ATM (#2873), ATR (#2790),
CHK2 (#2662), NOTCH3 (#2889), MCM7 (Santa Cruz
Biotechnology, Santa Cruz, CA, USA; sc-9966), CHK1
(sc-8408), BRCA1 (sc-642), FN1 (sc-9068), LASP-1
(Chemicon International, Billerica, MA, USA;
MAB8991), PTMA (Alexis Biochemical, San Diego, CA,
USA; 4F4) and b-actin (CalbioChem, San Diego, CA,
USA; #CP01). Signals were visualized after incubation
with recommended secondary antibody conjugated to per-
oxidase and the signal was developed using Pierce ECL
western blotting substrate (Thermo Fisher Scientiﬁc,
Rockford, IL, USA).
Matrigel invasion assay
Invasion was measured using the BD BioCoat
TM Tumor
Invasion System (BD Biosciences) as indicated by the
manufacturer. Brieﬂy, 1 10
6 LNCaP, PC-3 or 22Rv1
cells were transfected with 100nM control or pre-miR-1
oligos using Nucleofector Technology (Lonza Inc.
Walkersville, MD, USA) and cell line-optimized protocols
as deﬁned by the manufacturer. After 48h of growth in
6-well plates, cells were pre-labeled with growth media
containing 10mg/ml DilC12(3) ﬂuorescent dye (BD
Biosciences). Next, 2.5 10
4 cells in 500ml of serum-free
RPMI were seeded in triplicate into the apical cambers of
both Matrigel coated and non-coated Fluroblok
24-Multiwell insert systems. Basal chambers were ﬁlled
with 750ml of RPMI including 10% FBS as a chemo-
attractant. After 48h, cells that had migrated through
the membrane were imaged using an inverted ﬂuorescent
microscope (20 ) and quantiﬁed from at least three
images per well using ImageJ software. Data is expressed
as percent invasion through the Matrigel coated
membrane relative to the average number of cells
migrating through the non-coated membrane.
Clonogenic assay
Details can be found in Supplementary Data.
LASP1 and F-actin ﬂuorescence labeling and
determination of mitotic index
Assay details can be found in Supplementary Data.
DNA methylation analysis
Details can be found in Supplementary Data.
miR-1-133 cluster lentiviral construct and xenograft model
Lentiviral plasmid DNA was co-transfected with the
Invitrogen packaging plasmids into HEK293T cells to
generate VSV-g pseudotyped lentivirus particles. The
cells were re-fed with DMEM media, 10% FBS, 1%
Penn-Strep 24-h post-transfection and the culture super-
natant was harvested 48-h post-transfection. The crude
lentivirus stock was centrifuged and ﬁltered to remove
cells and other debris. Clariﬁed lentivirus was
concentrated using the Amicon ﬁlters, and virus titer
was determined using ﬂow cytometry-GFP detection.
Prostate cancer cells were transduced with modiﬁed-
Tween (Control) and miR-1-133 cluster lentiviral con-
struct, expanded and sorted for GFP-positive cells. To
allow for in vivo imaging of xenografts, all cells were
also transduced with lentiviruses packaged with the
pFerH_ffLuc2-mCherry construct (41). Xenografts were
carried out by dual ﬂank s.c. injections of 5- to
6-week-old athymic nu/nu nude mice (NCI-Animal
Genetics and Production Facility, Frederick, MD, USA)
with a 200-ml mixture containing 1 10
6 of control
(Tween) or miR-1-133 cluster infected cells suspended in
a 1:1 solution of growth media and high-concentration
Matrigel matrix (BD Biosciences). Tumor size was
measured and tumor volume was calculated using the fol-
lowing equation: tumor volume=(W
2 L)/2 formula.
For in vivo imaging, animals were intraperitoneally
injected with a solution of D-Luciferin (Caliper Life
Sciences, Alameda, CA, USA) and imaged with a
Xenogen IVIS system (Caliper Life Sciences, Alameda,
CA, USA) after 15–20 min following protocols provided
by the manufacturer. All mouse studies were performed in
accordance with Animal Study Protocols approved by the
Animal Care and Use Committee, National Cancer
Institute, National Institutes of Health.
Statistical analysis and bioinformatics
All statistical tests were two-sided, and an association was
considered statistically signiﬁcant with P-values <0.05.
The Kaplan–Meier survival method, Cox proportional-
hazards regression analysis, and the log-rank test of
equality of the survival function were used for disease
Nucleic Acids Research,2012, Vol.40, No. 8 3691recurrence analysis. Affymetrix and miR array expression
data from cell line-based experiments were analyzed with
customized R scripts (http://www.r-project.org) after data
normalization within R using robust multi-array average
(RMA) for normalized intensities and MAS5 detection
calls to ﬁlter out bad probes. Lists of differentially ex-
pressed genes were generated with the statistical analysis
of microarray (SAM) procedure and deﬁned using P-
values from two-sided t-tests, fold changes and/or false
discovery rate (FDR) cutoffs. We used BRB-ArrayTools
(http://linus.nci.nih.gov/BRB-ArrayTools) to analyze
mRNA and miR expression data in human prostate
tumors and metastases from a publically available data
set, deposited in NCBI GEO under accession number
GSE21032 (39). Calculation of P-values and fold changes
of differentially expressed genes were performed using the
Partek Genomics Suite software (Partek Inc, St. Louis, MI,
USA). Kaplan–Meier survival analysis was performed
using GraphPad Prism software (La Jolla, CA, USA).
Log-rank tests were performed on gene expression values
that were stratiﬁed using the median as cutoff. The
TargetScan database (http://www.targetscan.org) was
used to deﬁne miR seed sites within miR 30-UTRs. miR-1
targets were deﬁned within Partek based on the TargetScan
5.0 database. Target enrichment calculations, pathway
analysis and clustering, and heat maps were produced
usingin-houseWholePathwayScopesoftware,asprevious-
lydescribed(42–44).Clusteranalysesandheatmapoutputs
oftheseanalyseswerebasedonrankedFischerexacttestP-
values that were transformed into enrichment scores using
the formula [ log10(P-value)]. Connectivity mapping
(cmap) was carried out on altered gene lists using the web
interface http://www.broad.mit.edu/cmap and ﬁltered for
meanconnectivityscoresbetterthan±0.6andpermutation
P-values  0.05 for cmap query data with heat map output
showing permutation P-values expressed as  log10(P-
value). List Hits <2o rP-value >0.05 ﬁltering was used to
ﬂoor the scores to 0 for all heat maps. Differentially ex-
pressed gene lists were further analyzed with the Ingenuity
Pathways Analysis program (Ingenuity Systems, www.in-
genuity.com) to identify miR-1-related gene networks.
RESULTS
miR-1 is under-expressed in primary and metastatic
prostate cancer and is a candidate prognostic marker
Previously, we reported that miR-1 and miR-133(a) are
signiﬁcantly down-regulated in prostate tumors (26). We
followed up on this observation by studying mature miR-1
expression with qRT-PCR in the TRAMP mouse model
of prostate cancer (45). This study showed that
cancer-prone TRAMP mice at 20 week of age had only
20–30% of the miR-1 expression in their prostate when
compared with miR-1 expression in the prostate of same
age wild-type control animals (n=4 each group; data not
shown). To corroborate our ﬁndings, we analyzed a large
publicly available data set consisting of miR and mRNA
expression proﬁles for 99 primary tumors and 14 distant
metastasis and patient data for disease recurrence (39).
Consistent with our previous ﬁndings, both miR-1 and
miR-133a were found to be signiﬁcantly reduced in
primary tumor tissues (Figure 1). Furthermore, analysis
of the proﬁles for distant metastases revealed an addition-
al reduction in miR-1-133a cluster expression in these
lesions ( 40-fold) when compared with primary tumor
tissues. A separate genome-wide analysis of all miRs in
this data set showed that miR-1 was the most reduced
miR in metastatic tissue samples when compared with
primary tumors (P<1 10
 36). For comparison, we
also plotted the relative expression of the well
characterized miR-145 tumor suppressor (30,46) for the
same tissues (Figure 1). miR-145 followed a trend very
similar to that of the miR-1-133a cluster with an incre-
mentally reduced expression of this miR from adjacent
non-cancerous tissue to primary tumor to metastasis.
Next, we tested whether miR-1 and miR-133a are can-
didate prognostic markers. In a Kaplan–Meier analysis
for disease recurrence, we found that miR-1 was
associated with disease recurrence (Figure 2A). Tumors
that had reduced miR-1 levels below the median were sig-
niﬁcantly more likely to have an early recurrence than
tumors with above median miR-1 expression. The associ-
ation of miR-1 with disease recurrence was independent of
age and Gleason score in the adjusted Cox regression
analysis (hazard ratio=0.29; 95% conﬁdence interval:
0.1–0.9; high- versus low-tumor miR-1). We did not ﬁnd
the same association with survival for miR-133a, nor was
expression of the paralog miR-206-133b cluster associated
with recurrence (Supplementary Figure S1). To assess to
what extent predicted miR-1 target genes contribute to
early disease recurrence, we plotted the enrichment of
miR-1 target genes among all recurrence-associated
genes (% miR-1 targets among all mRNAs at a given
P-value for the association with disease recurrence) on a
log-rank test-based P-value scale (Figure 2B). When the
recurrence-associated mRNAs were sub-divided into
up-regulated and down-regulated transcripts in the
primary prostate tumors, we found a signiﬁcant enrich-
ment of miR-1 targets (‘% miR-1 target’) only among
those transcripts which predict recurrence and are also
up-regulated in the primary tumor, consistent with the
loss of miR-1 in these tumor tissues. This enrichment
increased with decreasing log-rank P-value (Figure 2B),
indicating a particular enrichment for miR-1 target tran-
scripts at the lowest false discovery for recurrence-
associated transcripts. Among the recurrence-associated
genes that are known miR-1 targets were NOTCH 3
(Figure 2C) and exportin-6 (Figure 2D). The ﬁndings
from our miR-1 target enrichment analysis support the
hypothesis that down-regulation of miR-1 in primary
tumors leads to an increased risk of disease recurrence
because of increased expression of oncogenic mRNAs
that are otherwise down-regulated by miR-1.
miR-1 family members are epigenetically regulated
Our studies showed that the miR-1-133a cluster is
under-expressed in cancerous lesions of the prostate.
Previously, methylation-mediated silencing of miR-1 was
found to occur in human hepatocellular carcinoma (37),
consistent with the presence of regulatory CpG islands
3692 Nucleic Acids Research, 2012,Vol.40, No. 8Figure 2. miR-1 is a prognostic marker. (A) Kaplan–Meier analysis of disease recurrence comparing high- versus low-miR-1 expression in the
primary tumor. Tumors that had miR-1 levels below the median were signiﬁcantly more likely to have an early recurrence (P=0.008; log-rank test).
(B) Enrichment of predicted miR-1 target transcripts among all recurrence-associated transcripts (‘% miR-1 target’) on a log-rank P-value scale for
recurrence (P-value for the association between a mRNA and disease recurrence). Disease recurrence-associated transcripts, sub-divided into either
up-regulated (‘up’) or down-regulated (‘down’) transcripts in the primary tumors, were plotted with their log-rank P-value from the recurrence
analysis against enrichment of transcripts that are predicted miR-1 targets (TargetScan 5.0-based percent miR-1 targets). Among 1541 transcripts
that were associated with recurrence at P   0.05 in the unstratiﬁed analysis, 61 were predicted miR-1 targets [P for enrichment of miR-1 targets
(Fisher’s exact-based) <0.001]. At more stringent P-value cutoffs (e.g. 10
 4 or 10
 5), the enrichment for miR-1 targets increased notably from 5% to
over 40%. (C) Kaplan–Meier analysis of disease recurrence comparing high- versus low-NOTCH3 expression in the primary tumor. Tumors that had
NOTCH3 levels above the median were signiﬁcantly more likely to have an early recurrence (P=0.004; log-rank test). (D) Kaplan–Meier analysis of
disease recurrence comparing high- versus low-XPO6 (exportin-6) expression in the primary tumor. Tumors that had XPO6 levels above the median
were signiﬁcantly more likely to have an early recurrence (P=0.02; log-rank test).
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Figure 1. miR-1-133 cluster expression in primary and metastatic prostate tissues. Relative expression levels of miR-1,  133a and 145 in primary
prostate tumors (n=99) and metastatic lesions (n=14). Data represent log2 expression values. P-values were calculated with an ANOVA-based post
hoc t-test.
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whether miR-1-133a is epigenetically silenced in pros-
tate cancer, LNCaP human prostate cancer cells were
treated with either the DNA hypomethylating agent,
5-azacytidine (5-AzaC) or the histone deacetylase inhibi-
tor, trichostatin A (TSA), or with the combination of the
two agents, and changes in global miR expression were
examined using the OSU microarray (see methods). We
observed that miR-1 and miR-133(a/b) expression was at
the detection limit in untreated LNCaP cells but expres-
sion was speciﬁcally re-activated by the combination of
5-AzaC and TSA (Figure 3B). This experiment also
showed that miR-206 and several other miRs
(Supplementary Table S1) are epigenetically silenced in
LNCaP cells. To further test, whether 5-AzaC alone can
increase miR-1 expression, LNCaP and 22Rv1 human
prostate cancer cells were treated in a second experiment
with 5mM 5-AzaC for 36h, and miR-1 expression was
evaluated by qRT-PCR. This experiment revealed
increased mature miR-1 expression in these cells after
5-AzaC treatment (Figure 3C). To address the question
whether miR-1 is promoter-methylated in the cancerous
prostate, we analyzed cancer tissue from four prostate
cancer patients with localized disease and the same
number of surrounding non-cancerous tissues. We per-
formed methylation analysis of the CpG island-81 within
the promoter of the miRNA-1-1 gene. This CpG island
was shown to be hypermethylated in the hepatocellular
carcinomas (37). From our analysis using EpiTect
Methyl qPCR Assay technology, we obtained evidence
that this locus shows detectable DNA methylation in all
analyzed prostate tissues, but hypermethylation was
only present in tumors (two out of four) and not in
the non-cancerous tissues (Supplementary Figure S2).
The data are consistent with ﬁndings from human
hepatocellular carcinoma and indicate that promoter
hypermethylation may contribute to reduced miR-1 ex-
pression in at least a subset of human prostate tumors.
miR-1-induced gene expression alterations in LNCaP cells
target cell cycle and DNA repair and show resemblance
with signatures induced by histone deacetylase inhibitors
To elucidate candidate effects of miR-1 in prostate cancer,
we up-regulated miR-1 in LNCaP cells using pre-miR
treatment and examined miR-1-induced gene expression
alterations on a global scale with Affymetrix arrays. For
comparison, we also introduced into these cells miR-206,
which is predicted to generate gene expression alterations
very similar to miR-1, and miR-27, which is functionally
unrelated to miR-1. The expression data for these miRs in
the LNCaP cells are shown in Supplementary Figure S3.
The expression of numerous mRNAs was found to be
altered by miR-1 (Supplementary Table S2) and the
other two miRs, miR-206 and miR-27, after exposure of
LNCaP cells to pre-miRs for 24h. When we queried the
lists of differentially expressed mRNAs for miR seed sites
within their 30-UTR using TargetScan, a signiﬁcant en-
richment for these sites was observed among the
down-regulated, but not up-regulated, transcripts for all
3 miRs, validating our experimental approach
(Supplementary Figure S4a and Supplementary Table
S3). Enrichment of predicted miR-1 and miR-206 targets
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for each miR. Red indicates increased expression of a miR (C) qRT-PCR levels showing re-expression of mature miR-1 in LNCaP and 22Rv1 human
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3694 Nucleic Acids Research, 2012,Vol.40, No. 8among all down-regulated genes reached signiﬁcant levels
of 1.35 10
 24 and 7.77 10
 26, respectively, in the
LNCaP cells, while exposure of these cells to the unrelated
miR-27 did not lead to any enrichment of these miR-1/
miR-206 targets among the down-regulated genes.
Moreover, miR-1 and miR-206 were found to regulate
abundance of many of the same transcripts
(Supplementary Figure S4b), as one would expect from
two homologous miRs. Collectively, the data indicate
that our experiment yielded a valid list of target genes
for miR-1.
Next, we queried the list of miR-1/miR-206-induced
gene expression alterations for their relationship with bio-
logical processes using gene ontology annotations and also
performed a cluster analysis for enrichment of differen-
tially expressed mRNAs in these processes. This type
of approach can reveal key cell functions that
are inﬂuenced by a miR, either directly or indirectly.
Several signiﬁcant relationships between down-regulated
mRNAs and speciﬁc biological processes were observed
(Supplementary Figure S5a). Two main clusters deﬁning
distinct cell functions were signiﬁcantly enriched for
mRNAs whose expression is reduced by miR-1 and
miR-206. Enriched cluster 1 included cell cycle, DNA
replication and mitosis-related processes, whereas
enriched cluster 2 contained DNA repair and cell cycle
checkpoint-related processes. Other analysis results
indicated miR-1-induced disturbances in chromosome seg-
regation, pointing to a candidate effect of miR-1 on actin
ﬁlament network organization by targeting genes like
LASP1, ﬁbronectin, exportin-6 or twinﬁlin-1/PTK9.
Among all biological processes, cell cycle and
DNA repair response had the greatest enrichment in
transcripts that were down-regulated by miR-1,
e.g. BRCA1 or CH(E)K1 (Supplementary Figure S5b).
Notable, however, we did not observe that these cell
cycle and DNA repair-related transcripts were particularly
enriched for miR-1 seed sites in their 30-UTR. A more
detailed pathway analysis using the union of miR-1 and
miR-206 down-regulated transcript lists identiﬁed two
miR-1/miR-206 inﬂuenced networks. Numerous tran-
scripts that encode for proteins in the origin recognition
complex (ORC), which is essential for the initiation of
DNA replication, were found to be repressed by miR-1/
miR-206 (Supplementary Figure S5c). This included tran-
scripts from the mini-chromosomal maintenance (MCM)
family of genes; MCM2, MCM4, MCM7, MCM10 and
cell division cycle-6 (CDC), CDC7, ORC6L and ORC1L.
Pathway analysis also identiﬁed a miR-1-regulated
network within the G2/M DNA damage checkpoint
(Supplementary Figure S5d): breast cancer 1 early onset
(BRCA1), CHK1, CDC25, CDC25, CDC25A, CDC25B/
C and CDK1.
Having made these observations, we further explored
the global effect of miR-1 in LNCaP cells by utilizing
Connectivity Map (cmap) web tools (47). This analysis
approach, also referred to as Gene Set Enrichment
Analysis, uses the Kolmogorov–Smirnov statistics-based
proﬁle pattern matching method and can be used to
compare the miR-1-induced gene expression alterations
in LNCaP cells with transcriptional signatures induced
by bioactive molecules that are curated in the cmap
database. Our analysis discovered signiﬁcant similarities
between several anticancer drug-induced gene signatures
and the miR-1-induced gene signature (Supplementary
Figure S6). Among the top ranked molecules were two
histone deacetylase inhibitors, vorinstat and trichostatin
A, indicating that conferring miR-1 expression to
prostate cancer cells led to gene expression alterations
similar to those of histone deacetylase inhibitors.
Validation of miR-1 altered genes
From our gene expression analysis experiments, it became
evident that pathways related to cell cycle control, DNA
damage response and actin ﬁlament network functions are
partly controlled by miR-1. Thus, we performed Western
blot analysis and 30-UTR reporter assays for miR inter-
ference with translation, using two human prostate cancer
cell lines, LNCaP and PC-3, and in the non-invasive
RWPE-1 human prostate epithelial cell line to further cor-
roborate the gene expression data (Figure 4). In this val-
idation step, we studied several predicted targets of miR-1,
such as FN1 (ﬁbronectin), LASP1 (LIM and SH3 protein
1) and PTMA (prothymosin alpha) that were found to be
signiﬁcantly down-regulated in pre-miR-1 treated LNCaP
cells, and also examined selected key genes in cell cycle
and DNA damage control (BRCA1, CHK1, MCM7).
The actin ﬁlament network-associated proteins encoded
by FN1 and LASP1 were found to be down-regulated
by miR-1, consistent with the array data and previous
ﬁndings that another protein in this pathway, exportin-6
(XPO6), is targeted by miR-1 in human prostate tumors
(26). We also conﬁrmed that BRCA1, CHK1, MCM7 and
PTMA are decreased by miR-1 at the protein level.
Introduction of miR-206 caused protein level alterations
very similar to miR-1, as one may expect (Figure 4A). In
contrast, the introduction of miR-106b, a miR function-
ally unrelated to miR-1, did not cause the same protein
expression alterations when examined in the RWPE-1 and
PC-3 cell lines (Figure 4B). Introduction of an antisense
oligo into immortalized RWPE1 cells to block miR-1 by
lock-nucleic acid (LNA) technology led to a modest
up-regulation of several of these proteins and also of
NOTCH3, an experimentally veriﬁed miR-1 target
(Figure 4C), consistent with miR-1 inhibition. Lastly, we
examined whether miR-1 may affect gH2A.X levels in
LNCaP cells. gH2A.X is a surrogate marker for DNA
double-strand breaks and is involved in a repair
pathway that includes BRCA1. Our examination of
gH2A.X marker expression showed that elevated miR-1
causes a reduction of histone H2A.X phosphorylation
(Figure 4A), commonly referred to as gH2A.X, suggesting
that some of the miR-1 effects may signal through the
gH2A.X pathway.
miR-1 may regulate cancer phenotypes by direct and
indirect mechanisms. We could not ﬁnd candidate miR-1
seed sites in the 30-UTR of key genes in cell cycle and
DNA damage control (e.g. BRCA1, CHK1 and MCM7),
suggesting that miR-1 may target these genes indirectly.
To further address this point, we performed analyses of
the 50-UTR and coding sequence of all miR-1/206
Nucleic Acids Research,2012, Vol.40, No. 8 3695down-regulated genes to identify additional candidate
miR-1 seed sites. This analysis showed that several cell
cycle/DNA damage gene transcripts contain candidate
miR-1 seed sites within their CDS or 50-UTR region
(Supplementary Table S4). For example, the BRCA-1
transcript contains a candidate miR-1 seed site in the
coding sequence. On the other hand, we were able to
identify potential seed sites in the 30-UTR of FN1,
LASP1 and PTMA. Therefore, we performed 30-UTR
reporter assays for miR-1 interference with translation
using reporter constructs containing wild-type and
mutant 30-UTRs of FN1, LASP1 and PTMA. XPO6
and NOTCH3 have previously been shown to be a direct
target by miR-1 or miR-206 (26,48). Thus, we included the
30-UTRs of these genes in our analysis as positive controls.
For all 30-UTR constructs, transfection of LNCaP cells
with miR-1 reduced luciferase activity of the wild-type
construct, and this reduction was attenuated when a
mutation was introduced into the predicted miR-1 seed
sites (Supplementary Figure S7). The ﬁndings indicate
that some of the miR-1 phenotypes in prostate cancer
cells could be mediated by miR-1-induced disturbances
of the actin ﬁlament network by directly targeting expres-
sion of FN1, LASP1 and XPO6, among other candidate
transcripts that encode actin binding partners.
miR-1 inhibits cell cycle progression and represses mitosis
and the proliferation of prostate cancer cells
Our gene expression analysis of the miR-1 effects in
LNCaP cells showed that this miR targets the cell cycle.
Thus, we performed a more in-depth cell cycle analysis of
pre-miR-1 and pre-miR-206 transfected LNCaP cells and
found that conferred expression of these miRs leads to a
signiﬁcant increase in the number of cells in S-phase
(Figure 5A). We further tested whether the number of
mitotic cells in cell culture is reduced after exposure to
these miRs. Consistent with our microarray data
showing that miR-1 down-regulates genes involved in
DNA replication and mitosis, the fraction of mitotic
LNCaP cells was signiﬁcantly reduced after treatment
with pre-miR-1 and pre-miR-206 oligos (Figure 5B).
Moreover, these miRs also reduced cell proliferation, as
shown for miR-1 in two human prostate cancer cell lines,
LNCaP and 22Rv1 (Figure 5C and D). Together, the
ﬁndings suggest that miR-1 may reduce proliferation of
prostate cancer cells by stalling them in S-phase and pre-
venting cell cycle progression.
miR-1 inhibits invasion and ﬁlipodia formation
The gene expression analysis of LNCaP cells transfected
with pre-miR-1 identiﬁed a group of down-regulated genes
that are part of a distinct expression programming
network, indicating that miR-1 may regulate the actin
ﬁlament network and cell motility (Figure 6A). Within
this network, several miR-1 targets are directly associated
with F-actin, such as LASP1, and CLCN3, while other
miR-1 targets, like G6PD and HDAC4, are indirectly
linked to F-actin and histone acetylation processes.
Thus, we examined whether miR-1 may affect invasiveness
of human prostate cancer cells. As shown in Figure 6B,
miR-1 indeed reduced matrigel invasion of prostate cancer
cells, with the strongest effect in the highly invasive PC3
cells. We also examined whether the cytoskeletal organ-
ization in prostate cancer cells is altered by miR-1.
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Figure 4. Effects of miR-1 on protein expression in LNCaP cells. (A) Western blot with protein extracts from LNCaP cells treated with either 30nM
of pre-miR-1, pre-miR-206 or scrambled miR negative control for 48h. (B) Western blot with protein extracts from RWPE-1 and PC-3 cells treated
with either 30nM of pre-miR-1, pre-miR-106b or scrambled miR negative control for 48h. (C) Immunoblotting of predicted miR-1 target genes in
non-invasive RWPE-1 cells transfected with inhibitory lock-nucleic acid (LNA) miR oligos targeting either miR-1 or miR-106b. Control cells were
transfected with unspeciﬁc LNA oligos. miR-106b was used to show speciﬁcity for miR-1. b-actin was used as a loading control and 50mg of protein
extract was loaded per lane. Immunoblotted proteins: mini-chromosomal maintenance-7 (MCM7), breast cancer 1 early onset (BRCA1), checkpoint
kinase 1 (CHK1), ﬁbronectin 1 (FN1), LIM and SH3 protein (LASP1), Notch homolog 3 (NOTCH3) and prothymosin alpha (PTMA).
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with pre-miR-1 led to a loss of ﬁlipodia ﬁlaments, as
shown in Figure 6C and D. The pre-miR-1 transfected
cells had F-actin being concentrated in inactive,
concentrated bundles with lacking ﬁlipodia extensions.
Filipodia formation is an essential part of cell motility
and is supported by actin polymerization into these ﬁla-
ments. The data suggest that miR-1 inhibits this process.
Preliminary data summarized in Supplementary Figure S8
indicate that miR-1 function is perhaps linked to F-actin
through regulation of LASP1, a gene which was found by
us to be signiﬁcantly down-regulated in miR-1 expressing
prostate cancer cells. LASP1 is a putative oncogene and
has a dual function as transcription factor and F actin
binding protein which co-localizes with F-actin at periph-
eral cell extensions including ﬁlipodia and lamellipodia
(49,50). We found that miR-1 induces re-localization
of LASP1 from the nucleus into the cytoplasm
(Supplementary Figure S8), which could be a compensa-
tory process following LASP-1 down-regulation by
miR-1.
Altered DNA damage response to radiation in prostate
cancer cells transfected with pre-miR-1 or expressing
the complete miR-1-133 cluster
Our array results showed that miR-1 repressed, at least
temporarily, the expression of key genes in the DNA
damage response pathway. Furthermore, protein extracts
from pre-miR-1 transfected LNCaP cells showed reduced
gH2A.X. Thus, we were interested to see whether miR-1
would affect the response of prostate cancer cells to
radiation-induced DNA damage. For this purpose, we ini-
tially transfected LNCaP and 22Rv1 cells with pre-miR-1
or control oligos and exposed these cells to 6Gy
g-radiation, followed by 24h of cell culture, in order to
study protein expression of selected DNA damage
Figure 5. Expression of miR-1 alters cell cycle kinetics and suppresses mitosis and cell proliferation in prostate cancer cells. (A) FACS-based cell
cycle analysis of LNCaP cells transfected with 30nM control, pre-miR-1 or pre-miR-206 oligos. Shown is the mean percentage±SD of propidium
iodide-labeled cells in G1, S and G2/M phases of the cell cycle from three independent experiments. (B) Mitotic ﬁgures counted via DAPI staining.
Three ﬁelds per miR treatment from three independent experiments were counted and presented as percentage mitotic cells. Proliferation of (C)
LNCaP and (D) 22Rv1 cells transfected with 30nM of either control or miR-1 mimic oligos. The results are given as means±SD. n=6 from one
representative experiment. P-values were calculated using Student’s t-test; *P<0.01, **P<0.0001.
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Figure 6. miR-1 targets F-actin related genes and causes changes in the cellular arrangement of F-actin. (A) Network of miR-1 targets that
highlights the candidate regulation of the F-actin ﬁlament network and histone acetylation by miR-1. (B) Transwell invasion experiments show
that miR-1 can inhibit the invasive potential of human prostate cancer lines. Scrambled control versus pre-miR-1 transfected cells: P<0.05 (Student’s
t-test, n=3). (C) Fluorescence stain for F-actin (red) and merged stains for F-actin, DAPI (blue) and LASP1 (green) in LNCaP and 22Rv1 prostate
cancer cells transfected with either control oligos or pre-miR-1. Pre-miR-1 transfected cells showed a generally increased F-actin stain with F-actin
being concentrated in inactive, concentrated bundles, as shown by the strong punctate red ﬂuorescence and highlighted by the white arrows (in
‘Pre-miR-1’). Pre-miR transfected cells showed a signiﬁcant reduction in ﬁlipodia extensions, which would arise from the base where the F-actin
accumulates. For comparison, arrows highlight the ﬁlipodia ﬁlaments of the control cells (in ‘Control’). (D) Quantitative assessment of the reduction
in ﬁlipodia extensions and increase in F-actin bundles by miR-1. Filipodial extensions and F-actin bundles were counted in at least four ﬁelds for an
average of about 1700 cells per group and shown as a percent of total cells per ﬁeld ±SD. P-values were calculated using Student’s t-test; *P<0.01,
**P<0.001,***P<0.0001.
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inﬂuenced the expression levels of some DNA damage
response genes, leading to increased expression of 53BP1
and reduced levels of gH2A.X protein in both cell lines
and to a modest up-regulation of other key regulators in
the mammalian DNA damage response, such as ATM
(ataxia telangiectasia, mutated) and ATR (ATM and
Rad3-related), in the 22Rv1 cells (Supplementary Figure
S9a). To further identify the kinetics that led to a reduced
gH2A.X accumulation in miR-1 expressing prostate
cancer cells, we either transfected 22Rv1 cells with
pre-miR-1 or infected them with a lentiviral construct to
express the complete miR-1-133 cluster, then irradiated
the cells with 6Gy and prepared cell extracts at various
time points post-irradiation. This experiment revealed that
miR-1- and miR-1-133 cluster-expressing cells initially
accumulate more gH2A.X but remove gH2A.X more
quickly than the control cells, leading to reduced
gH2A.X levels at later time points (Supplementary
Figures S9b and S9c). Lastly, we examined whether
miR-1 would inﬂuence clonogenic expansion of irradiated
cells. Both pre-miR-1 transfected and miR-1-133 cluster
expressing 22Rv1 cells were exposed to various amounts
of radiation and plated at low density to assess radiation
survival, when compared with the control cells, using a
traditional clonogenic survival assay as described in
Supplementary Methods. 22Rv1 cells with miR-1 expres-
sion were found to have fewer radiation-surviving cells,
when compared to the control cells, albeit the difference in
survival between them was rather modest (Supplementary
Figures S9d and S9e). Taken together, our data point to
changes in the DNA repair response and to a moderately
increased radiosensitivity of miR-1 expressing prostate
cancer cells, consistent with the observed increased sensi-
tization of human lung cancer cells to doxorubicin toxicity
by miR-1 (38).
Suppression of prostate cancer xenograft growth
by the miR-1-133 cluster
The inﬂuence of the complete miR-1-133 cluster on xeno-
graft growth was tested in two subcutaneous tumor
models using the 22Rv1 and LNCaP prostate cancer cell
lines. 22Rv1 and LNCaP cells were infected with a
lentiviral construct engineered to confer miR-1-133 ex-
pression (see Supplementary Data). Cluster expression
was conﬁrmed by qRT-PCR and showed a 10- to
100-fold up-regulation of these miRs in the infected cell
lines. Overexpression of the miR cluster led to reduced
tumor growth of 22Rv1 cells, as shown for two independ-
ent experiments (Figure 7A–C). In an additional xenograft
experiment with LNCaP cells, we did not observed the
same signiﬁcant differences in the tumor volumes
between the miR-1-133 and the vector control group.
However, we observed a signiﬁcant reduction of the
number of tumors that developed in the miR-1-133
group when compared to the vector control (Figure 7D).
Together, the ﬁndings are consistent with a tumor sup-
pressor function by the miR-1-133 cluster.
DISCUSSION
The current study provides novel evidence that miR-1 has
tumor suppressor activity in human prostate cancer and is
associated with disease recurrence and metastatic spread.
These ﬁndings are corroborated by a recent report in
which the authors used Solexa deep sequencing of 50
organ-conﬁned tumors and found miR-1 to be among
the most down-regulated miRs in prostate tumors when
compared with non-cancerous prostate tissue (51). The
study by Martens-Uzunova et al. also observed, consistent
with our observations, that miR-1 is further down-
regulated in cancer progression, based on their analysis
of lymph node metastases, and is a component of a
miR-based predictor for disease outcome. However, our
study is now showing, based on the analysis of a larger
data set, that miR-1 alone can predict disease recurrence.
Furthermore, oncogenic miR-1 target genes, such as
NOTCH3, have been associated with recurrence of
prostate cancer in our and other studies (32), suggesting
that loss of miR-1 leads to increased expression of onco-
genes, driving the association of miR-1 with disease
outcome. This hypothesis is supported by our analysis of
the mRNA expression proﬁles in the Taylor data set (39),
showing that mRNA-based predictors of disease recur-
rence are enriched for miR-1 target transcripts. Other
studies observed that the miR-1 homolog, miR-206, is a
candidate tumor suppressor in both rhabdomyosarcoma
development (52) and breast cancer metastasis (8), while
also inducing apoptosis in a cell-based system of cervical
cancer (48). The study by Tavazoie et al. (8) observed that
miR-206 induces morphological changes in breast cancer
cells, consistent with our observation that miR-1 inhibits
formation of ﬁlipodia in prostate cancer cells. Thus, both
miR-1 and miR-206 may exert similar tumor suppressor
activities in cancer initiation and progression in various
cancer types, even though we did not observe that
miR-206 expression was a predictor of disease recurrence
in our study.
miR-1 expression was thought to be largely restricted to
heart and skeletal muscle tissue because miR-1-133 cluster
expression is highest in these tissues but low or absent in
most other tissues (33). However, more recent studies
clearly demonstrated that miR-1 is expressed in
non-cancerous human epithelial cells of the liver and
lung (37,38). These authors also showed that miR-1 is
functional in epithelial cells and has tumor suppressor-like
properties, consistent with the ﬁndings in the current
study. Reminiscent of ﬁndings in human liver cancer
(37), we also observed that down-regulation of miR-1 in
prostate cancer cells is most likely due to promoter
silencing by epigenetic mechanisms. We could not detect
miR-1 expression in the metastatic PC-3 and DU145
human prostate cancer cell lines by a highly sensitive
qRT-PCR assay for mature miR-1, but observed a re-
maining low expression above the detection limit in the
22Rv1 and LNCaP cancer cell lines and a low expression
in the immortalized RWPE-1 human prostate epithelial
cells. Yet, introduction of antisense miR-1 oligos by
LNA technology into the RWPE-1 cells led to the
up-regulation of several miR-1 target genes, indicating
Nucleic Acids Research,2012, Vol.40, No. 8 3699that even a low expression of miR-1 in these cells is sufﬁ-
cient to partly repress oncogenic target genes like
NOTCH3.
Our functional analysis of miR-1 expression in cancer
cell lines pointed to a tumor suppressor function that
targets processes related to cell cycle progression and cell
motility. Additional mechanisms, of a more indirect
nature, seem to inﬂuence DNA repair pathways and spe-
ciﬁcally the gH2A.X signaling pathway as a consequence
of miR-1 expression. Other miRs have been described that
target H2A.X and suppress DNA repair, rendering cells
hypersensitive to genotoxic drugs (53). Thus, loss of these
miRs would make a cancer cell more resistant to cancer
therapy, which has been observed for miR-1 in lung cancer
(38). Taken together, our data point to changes in the
DNA repair response and to a moderately increased
radiosensitivity of miR-1 expressing prostate cancer cells,
consistent with the observed increased sensitization of
human lung cancer cells to doxorubicin toxicity by
miR-1 (38). A reduced sensitivity of prostate tumors
with low miR-1 to radiation therapy would be one
possible explanation why low-miR-1 expression in
human prostate tumors is associated with early disease
recurrence.
Because numerous miR-1 targets in LNCaP cells were
found by us to be actin ﬁlament-associated proteins, it is
plausible that some of the observed miR-1 tumor suppres-
sor effects in solid tumors are in fact caused by a disrup-
tion of actin cytoskeleton dynamics, leading to inﬁdelities
in chromosomal segregation and aberrant mitotic events,
which in turn activate cell cycle checkpoints, leading to a
stalled S-phase as we observed. Future research in animal
models of prostate cancer, including tissue-speciﬁc
knockout of miR-1, can address these questions since we
observed that the loss of miR-1 in cancer development is
recapitulated in the TRAMP mouse model of prostate
cancer. The inhibition of cell cycle progression in epithelial
cells would also explain why miR-1 is only weakly ex-
pressed in most epithelial cells, and why members of the
miR-1-133 cluster are among the most frequently
down-regulated miRs in solid human cancers including
prostate cancer (4,26,36,51). Thus, it is not surprising
that the miR-1-133 locus is epigenetically silenced in
solid tumors.
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Figure 7. miR-1-133 cluster suppresses xenograft growth of prostate cancer cells. (A) Representative in vivo images of mice injected with 22Rv1 cells
for 3 weeks. Cells were infected with lentiviral constructs either encoding both the complete miR-1-133 cluster and a luciferase reporter gene
(miR-1-133) or encoding only the luciferase reporter gene (control). (B) Representative tumor size from this experiment (n=6 per experimental
group). Tumors were resected 3 weeks after initial cell inoculation. (C) Control tumors were signiﬁcantly larger than tumors resected from animals
inoculated with 22Rv1 cells that expressed the miR-1-133 cluster. Two independent experiments are shown. Average±SEM for tumor size in the
control and miR 1-133 groups (n=20 xenografts per group) at 3-week post-inoculation. P-values calculated via Student’s t-test. (D) Tumor growth
of LNCaP cells expressing lentiviral constructs either encoding both the complete miR-1-133 cluster and a luciferase reporter gene (‘miR-1-133’) or
encoding only the luciferase reporter gene (‘control’). Xenografts were grown for 3 weeks with n=20 xenografts per group. There was a signiﬁcant
difference in tumor burden between the two groups with a reduced rate of tumor development in mice that were inoculated with miR-1-133 cluster
expressing cells. Results are shown with P-values calculated using the Student’s t-test.
3700 Nucleic Acids Research, 2012,Vol.40, No. 8While our study showed that miR-1 is a candidate
tumor suppressor, future studies are needed to further
deﬁne the tumor suppressor function of miR-1 in the
prostate. Currently, we do not know the relative contribu-
tion of miR-1 expression in tumor-associated stromal cells
to the poor outcome signature described in this and other
studies. Mir-1 is expressed in stromal cells of the prostate,
though a sensitive qRT-PCR is needed to detect the ex-
pression of miR-1 in these cells (51). Thus, down-
regulation of miR-1 in both the tumor epithelial and
stromal cells may contribute to the association of miR-1
expression with prostate cancer outcomes. One may
predict that miR-1 exerts functions in stromal cells
similar to those described by our study, but miRs are
known to have cell type-speciﬁc properties (54,55). An
additional mechanism that may deﬁne miR expression in
the prostate is exosome-mediated transfer of miRs
between cells. It has been shown that cells can transfer
miRs and mRNAs to neighboring cells by this mechanism,
leading to detectable protein expression of mRNA-
encoded transcripts after exosomal uptake (56). How efﬁ-
cient this mechanism is in transferring RNA from cell to
cell in human tissues remains to be resolved.
The application of the cmap analysis indicated that
miR-1-mediated tumor suppressor effects are globally
similar to those of histone deacetylase inhibitors. The
ﬁnding suggests that functional restoration of miR-1 in
prostate tumors would have a therapeutic activity com-
parable to these compounds. This similarity in activity
between miR-1 and histone deacetylase inhibitors could
arise from independent mechanisms leading to common
global expression changes. miR-1 may also directly
target genes in the histone deacetylase pathway. Indeed,
it has been shown that miR-1 targets histone deacetylase 4
(HDAC4), leading to a reduced expression of this
deacetylase (37,38). Suppression of HDAC4 may contrib-
ute to some of the miR-1 tumor suppressor activity
because this enzyme is a candidate oncogene in colon
cancer and could be involved in the development of
castration-insensitive prostate cancer (57,58). We also
observed that HDAC4 is down-regulated by miR-1/
miR-206 in prostate cancer cells, based on our gene ex-
pression data, consistent with our hypothesis that the
underlying mechanisms for many of the miR-1-induced
phenotypes in prostate cancer are higher order chromo-
somal and epigenetic effects by this miR.
In summary, our work describes miR-1 is a candidate
tumor suppressor and potential prognostic marker in
human prostate cancer. Future studies are needed to cor-
roborate the association between miR-1 and prostate
cancer outcomes and should further deﬁne the mechan-
isms that link this marker to disease recurrence and
cancer metastasis and also examine how this knowledge
can be used to target this pathway in cancer therapy.
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